In Ionis Pharmaceuticals Inc.\u2019s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and genetic disease hereditary angioedema (HAE). The approval came as scheduled as the NDA had a PDUFA date of Aug. 21. Dawnzera now joins a market with previously approved drugs for the rare, genetic, life-threatening condition, as well as other companies with HAE drugs in development.<\/p>\n
BioWorld<\/a> Regulatory<\/a> Dermatologic<\/a> Antisense<\/a> FDA<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"In Ionis Pharmaceuticals Inc.\u2019s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as…\n","protected":false},"author":2,"featured_media":15045,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[272],"tags":[13160,13694,13700,13702,13699,18,2898,13696,458,13697,19,13695,17,13698,2912,13701,133],"class_list":{"0":"post-15044","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-antisense","9":"tag-bioworld","10":"tag-dawnzera","11":"tag-dermatologic","12":"tag-donidalorsen","13":"tag-eire","14":"tag-fda","15":"tag-genetic-diseases","16":"tag-genetics","17":"tag-hereditary-angioedema","18":"tag-ie","19":"tag-ionis-pharmaceuticals-inc","20":"tag-ireland","21":"tag-prophylactic-therapies","22":"tag-rare-disease","23":"tag-regulatory","24":"tag-science"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/15044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=15044"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/15044\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/15045"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=15044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=15044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=15044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}